Loading clinical trials...
Loading clinical trials...
An Observational Study to Assess Real-world Patient Characteristics, Clinical Course, and Treatment Patterns for Symptomatic Patients With Arrhythmogenic Cardiomyopathy (ACM) Due To a PlaKoPhilin-2 Pathogenic Variant (PKP2)
Conditions
Locations
6
United States
Leland Stanford Junior University
Redwood City, California, United States
Johns Hopkins University
Baltimore, Maryland, United States
Northshore University Healthsystem Research Institute
Columbia, Maryland, United States
University of Michigan
Ann Arbor, Michigan, United States
Henry Ford Hospital
Detroit, Michigan, United States
University of Rochester
Rochester, New York, United States
Start Date
January 23, 2024
Primary Completion Date
July 1, 2027
Completion Date
September 1, 2027
Last Updated
May 16, 2025
NCT07354646
NCT05885412
Lead Sponsor
Lexeo Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions